Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Massard

Showing results (31-40 of 364) with videos related to

Pageof 37
Sort By:
Oncotargets and Therapy|May 2, 2019
Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potentialCapucine Baldini, Stéphane Champiat, Perrine Vuagnat, et al.
Expert Review of Anticancer Therapy|March 1, 2018
Durvalumab in urothelial cancersPernelle Lavaud, Zineb Hamilou, Yohann Loriot, et al.
Bulletin Du Cancer|December 17, 2011
[Chromosomal rearrangements and fusion genes in carcinoma]Christophe Massard, Nathalie Auger, Ludovic Lacroix, et al.
European Urology|April 30, 2015
Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?Laurence Albiges, Yohann Loriot, Christophe Massard, et al.
Bulletin Du Cancer|August 21, 2025
[TRANSFORM-O: A new training program in translational research offered by the French Society of Cancer (SFC) and the French National College of Oncology Teachers (CNEC)]Stanislas Quesada, Camille Tlemsani, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2020
Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?Sophie Postel-Vinay, Christophe Massard, Jean-Charles Soria
The Lancet. Oncology|April 3, 2025
Innovative, early-phase clinical trials of drug-radiotherapy combinationsAntonin Levy, Christophe Massard, Stefan Michiels, et al.
Expert Review of Anticancer Therapy|August 28, 2015
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerKarim Fizazi, Laurence Albiges, Yohann Loriot, et al.
Bulletin Du Cancer|May 6, 2014
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone]Emilie Boissier, Yohann Loriot, Stéphane Vignot, et al.
Bulletin Du Cancer|October 25, 2016
[Localized prostate cancer: Changes are still expected]Stéphane Vignot, Jacques-Olivier Bay, Christophe Massard, et al.
Pageof 37

Showing results (31-40 of 364) with videos related to

Sort By:
Pageof 37
Oncotargets and Therapy|May 2, 2019
Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potentialCapucine Baldini, Stéphane Champiat, Perrine Vuagnat, et al.
Expert Review of Anticancer Therapy|March 1, 2018
Durvalumab in urothelial cancersPernelle Lavaud, Zineb Hamilou, Yohann Loriot, et al.
Bulletin Du Cancer|December 17, 2011
[Chromosomal rearrangements and fusion genes in carcinoma]Christophe Massard, Nathalie Auger, Ludovic Lacroix, et al.
European Urology|April 30, 2015
Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?Laurence Albiges, Yohann Loriot, Christophe Massard, et al.
Bulletin Du Cancer|August 21, 2025
[TRANSFORM-O: A new training program in translational research offered by the French Society of Cancer (SFC) and the French National College of Oncology Teachers (CNEC)]Stanislas Quesada, Camille Tlemsani, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2020
Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?Sophie Postel-Vinay, Christophe Massard, Jean-Charles Soria
The Lancet. Oncology|April 3, 2025
Innovative, early-phase clinical trials of drug-radiotherapy combinationsAntonin Levy, Christophe Massard, Stefan Michiels, et al.
Expert Review of Anticancer Therapy|August 28, 2015
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerKarim Fizazi, Laurence Albiges, Yohann Loriot, et al.
Bulletin Du Cancer|May 6, 2014
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone]Emilie Boissier, Yohann Loriot, Stéphane Vignot, et al.
Bulletin Du Cancer|October 25, 2016
[Localized prostate cancer: Changes are still expected]Stéphane Vignot, Jacques-Olivier Bay, Christophe Massard, et al.
Pageof 37